Why is there a legal crackdown on compounded GLP-1 medicines in South Africa?

The High Court in Pretoria dismissed an appeal by compounding pharmacy iDexis, upholding an interim ban on manufacturing compounded semaglutide. This legal action is tied to ongoing investigations by SAHPRA and the South African Pharmacy Council to protect public health.

How much do registered GLP-1 weight-loss drugs cost in South Africa?

Registered GLP-1 medicines are highly expensive, with monthly costs typically ranging from R2,500 to R6,000 depending on the dose. Some registered alternatives can cost patients between R4,000 and R6,000 per month.

Are there financial options to help South Africans afford GLP-1 treatments?

Yes, programs like Obiflex have introduced interest-free buy-now-pay-later instalment plans to help patients spread the cost of their monthly treatment. These structured programs also provide virtual doctor consultations, health coaching, and delivery.

What are the risks of buying unregulated GLP-1 peptides online in South Africa?

Unregulated peptides sold online or on social media carry serious health risks and may have inaccurate dosages, with discrepancies of up to 40% reported. SAHPRA and the South African Pharmacy Council urge consumers to only buy scheduled medicines through accredited pharmacies.

Does private health insurance in South Africa cover GLP-1 drugs for weight loss?

Major private health plans like Discovery generally do not provide a dedicated chronic-medicine benefit for GLP-1 drugs when used specifically for obesity. This forces many patients to pay for their treatment out-of-pocket or use day-to-day benefits.

How many people in South Africa are affected by the ban on compounded GLP-1s?

The crackdown on illegal compounding is estimated to affect up to 300,000 South Africans who previously relied on cheaper, unregistered GLP-1 products. These patients now face the choice of paying for expensive registered alternatives or risking unsafe, unregulated sources.

GLP-1 drug crackdown and new payment options in South

South Africa has seen a sharp regulatory push against illegal compounding of GLP-1 weight-loss medicines, while new buy-now-pay-later schemes aim to make approved treatments more affordable.

Legal crackdown on compounding GLP-1 medicines

On 11 September 2026 the High Court in Pretoria dismissed iDexis’ application for leave to appeal an interim order that bars the pharmacy from making medicines containing the GLP-1 semaglutide, the active ingredient in Ozempic and Wegovy (Business Day, 11 September 2026). The order is linked to ongoing investigations by the South African Health Products Regulatory Authority (SAHPRA) and the South African Pharmacy Council (SAPC) (Business Day, 11 September 2026).

In June 2026 the court upheld an application brought by Novo Nordisk that resulted in the interim ban on iDexis’ compounded semaglutide products (Business Day, 11 September 2026). The company had already stopped compounding semaglutide and tirzepatide, the active ingredient in Mounjaro, after the June order (Business Day, 11 September 2026). SAPC registrar Vincent Tlala confirmed that iDexis’ registration is under review and that the pharmacy can operate only as a community pharmacy, not as a manufacturer (Business Day, 11 September 2026).

The Pharmaceutical Task Group welcomed the decision, saying it reinforces the role of regulators in protecting public health (Business Day, 11 September 2026).

Rising cost of registered GLP-1 medicines

Approved GLP-1 medicines remain expensive. Moneyweb reported on 29 September 2026 that the monthly cost of GLP-1 drugs ranges from R2 500 to R6 000 depending on the dose (Moneyweb, 29 September 2026). The high demand for these medicines has driven some patients to seek cheaper, illicit alternatives (Moneyweb, 29 September 2026).

Later, Cape Town ETC highlighted that registered alternatives could cost between R4 000 and R6 000 a month (Cape Town ETC, 4 October 2026). The price gap raises concerns that patients may turn to unregulated sources (Cape Town ETC, 4 October 2026).

Buy-now-pay-later schemes for GLP-1 treatment

In response to affordability challenges, the doctor-led health-management programme Obiflex introduced interest-free instalment plans for GLP-1 medicines. Moneyweb noted that patients can now spread the cost of their monthly treatment using buy-now-pay-later (BNPL) products (Moneyweb, 29 September 2026). The programme pairs low-dose GLP-1 treatment with structured coaching, aiming for up to 10% body-weight loss over six months; lower doses are more affordable but may lead to slower weight loss (Moneyweb, 29 September 2026).

Bizcommunity provided the specific payment structure: a three-month programme costs R1 499 per month over five payments, while a six-month programme costs R1 999 per month over nine payments (Bizcommunity, 29 September 2026). Both options include virtual doctor consultations, health coaching and door-to-door delivery (Bizcommunity, 29 September 2026).

Obiflex’s co-founders – Shaun Barns, Dr Riaz Motara, Jeff Miller and Moshe Unterslak – emphasized that the goal is to make the medicine affordable while providing medical oversight (Bizcommunity, 29 September 2026). The company also partnered with a leading pharmaceutical manufacturer to ensure a legitimate supply chain (Bizcommunity, 29 September 2026).

Impact on patients and safety warnings

The crackdown on illegal compounding is estimated to affect up to 300 000 South Africans who previously accessed cheaper, unregistered GLP-1 products (News24, 3 October 2026; Channel Africa, 3 October 2026). Obiflex warned that patients who cannot afford registered medicines may seek unregulated sources, exposing them to products with inaccurate dosages – discrepancies of up to 40% have been reported (Channel Africa, 3 October 2026).

SAHPRA has repeatedly cautioned consumers to obtain scheduled medicines only through accredited pharmacies and to avoid online or social-media sellers (Cape Town ETC, 4 October 2026). The South African Pharmacy Council’s CEO Vincent Tlala echoed these warnings, stressing that unregistered peptides can pose serious health risks (EWN, 1 October 2026).

Growing demand and insurer response

Discovery, the country’s largest private-health plan, saw claims for GLP-1 medicines nearly triple to 61 200 members over the three years ending 2025, with an average treatment duration of 5.4 months (News24, 3 October 2026; Bloomberg, 1 October 2026). However, the plan does not provide a dedicated chronic-medicine benefit for obesity-related use, leaving many patients to pay out-of-pocket (News24, 3 October 2026).

These trends underline the tension between high demand, regulatory enforcement and affordability, and they highlight the role of new financing models such as Obiflex’s BNPL scheme in bridging the gap.

GLP-1 drug crackdown and new payment options in South Africa

Legal crackdown on compounding GLP-1 medicines

Rising cost of registered GLP-1 medicines

Buy-now-pay-later schemes for GLP-1 treatment

Impact on patients and safety warnings

Growing demand and insurer response

Frequently asked questions

Sources